Urinary bladder cancer is a relatively common condition. A significant proportion of intermediate and highly malignant tumors recur and progress to invasive cancer. Various pharmaceutical agents have been tested in different regimens of intravesical treatment to prevent recurrence and progression. Currently, the standard treatment for non-invasive bladder cancers is the immediate, -after complete tumor resection- injection of a chemotherapeutic agent. For patients at intermediate-risk, a series of intravesical chemotherapy or immunotherapy for a 6-week period is suggested.
Intravesical installation of pharmaceutical agents to prevent recurrence and progression of superficial bladder cancer.
Perletti, Gianpaolo
2020-01-01
Abstract
Urinary bladder cancer is a relatively common condition. A significant proportion of intermediate and highly malignant tumors recur and progress to invasive cancer. Various pharmaceutical agents have been tested in different regimens of intravesical treatment to prevent recurrence and progression. Currently, the standard treatment for non-invasive bladder cancers is the immediate, -after complete tumor resection- injection of a chemotherapeutic agent. For patients at intermediate-risk, a series of intravesical chemotherapy or immunotherapy for a 6-week period is suggested.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
